|

Mesothelioma Patients and Alternative Treatment

Mesothelioma Patients and Alternative Treatments

A study from Stanford University describes two mesothelioma patients who experienced an improvement in their condition without clinical treatment. This is a rare occurrence for patients with mesothelioma, even with the usual treatment.

Mesothelioma is an aggressive cancer that grows in the lining of organs. This usually happens in the lungs or abdomen. It can also occur in the testis and the heart.

Mesothelioma is caused by exposure to asbestos and can be hard to treat. Multimodal treatment is a common option because it involves more than one type of treatment. These are usually chemotherapy, radiation, and surgery.

These types of treatments can be very hard on the body. Patients who are already frail when they arrive at the hospital for treatment may not be eligible for this aggressive treatment plan. They may also decide they don’t want that kind of treatment.

This study reports on two patients with diagnosed mesothelioma who did not receive any treatment. Despite this, they experienced an improvement in their condition.

Treatment Pathways

The first patient was a 71-year-old man with stage II malignant pleural mesothelioma. He declined conventional treatment and chose to use alternative treatment.

The patient stopped smoking and participated in deep-breathing exercises and meditation. He also started taking small amounts of ayahuasca. This is a type of tea used by native people in the Amazon, and it may help to reduce inflammation. There is no evidence that Ayahuasca will treat cancer.

Six months after his diagnosis, a scan of the patient’s chest showed that the mesothelioma had almost entirely disappeared.

After three years, the patient developed mesothelioma again. This time, he received radiation therapy that provided positive results.

The second patient was a 79-year-old man with Parkinson’s disease and prostate cancer. He was diagnosed with mesothelioma after going to the hospital for a bad cough. He was scheduled to receive multimodal treatment. Before treatment began, a routine scan showed that the mesothelioma was shrinking on its own. The patient remained free of mesothelioma up to 8 months after his diagnosis.

What Does This Mean for Mesothelioma Treatment?

These cases of mesothelioma healing on its own are extremely rare. In these two cases, the study authors noted high levels of immune system activity. This might support the use of immunotherapy to treat mesothelioma. Immunotherapy helps the body to fight mesothelioma using its own immune system.

Source

Nief CA, No HJ, Louie CY, Vitzthum L, Das M. Regression of Malignant Pleural Mesothelioma in Absence of Chemotherapy or Surgery: A Case Series [published online ahead of print, 2022 Oct 13]. Clin Lung Cancer. 2022;S1525-7304(22)00214-5. doi:10.1016/j.cllc.2022.10.002

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…